SCHEMBL17522780

SCHEMBL17522780

Cc1n[nH]c(C)c1CCCOc1cccc(C(C)(F)F)c1

nearest known ligand 0.69

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 6/20 0.69
▸ LMNA P02545 7/20 0.64
▸ HTT P42858 3/20 0.64
▸ NPSR1 Q6W5P4 2/20 0.64
▸ SMN1; SMN2 Q16637 6/20 0.59
▸ ATM Q13315 1/20 0.59
▸ MEN1 O00255 4/20 0.56
▸ KMT2A Q03164 4/20 0.56
▸ ALDH1A1 P00352 1/20 0.56
▸ TTR P02766 1/20 0.52
▸ MAPT P10636 5/20 0.51
▸ GAA P10253 1/20 0.50
▸ MAPK1 P28482 1/20 0.48
▸ TSHR P16473 1/20 0.47
▸ RECQL P46063 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19801753 0.91 HSD17B10 (0.70) HSD17B10LMNAHTTNPSR1SMN1; SMN2
SCHEMBL17495595 0.76 HSD17B10 (0.69) HSD17B10LMNAHTTNPSR1SMN1; SMN2
SCHEMBL17522785 0.73 SMN1; SMN2 (0.78) HSD17B10LMNAHTTNPSR1SMN1; SMN2
SCHEMBL12218179 0.72 SMN1; SMN2 (0.66) HSD17B10LMNAHTTNPSR1SMN1; SMN2
SCHEMBL15158388 0.69 TTR (1.00) HSD17B10LMNAHTTNPSR1SMN1; SMN2
SCHEMBL22610055 0.68 SMN1; SMN2 (0.88) HSD17B10LMNAHTTNPSR1SMN1; SMN2
SCHEMBL15828247 0.67 TTR (0.71) HSD17B10LMNAHTTNPSR1SMN1; SMN2
SCHEMBL21618544 0.67 TTR (0.62) HSD17B10LMNAHTTNPSR1SMN1; SMN2
SCHEMBL19801754 0.66 SMN1; SMN2 (0.72) HSD17B10LMNAHTTNPSR1SMN1; SMN2
SCHEMBL22315310 0.66 SMN1; SMN2 (0.63) HSD17B10LMNAHTTNPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180021446-A1 SYSTEMS FOR STABILIZING AND DELIVERING ACTIVE AGENTS MAHA THERAPEUTICS, INC. 2018-01-25 — — US disclosed
US-20160045609-A1 CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE MAHA THERAPEUTICS, INC. 2016-02-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180021446-A1 SYSTEMS FOR STABILIZING AND DELIVERING ACTIVE AGENTS SERPINA6, SERPINC1, SERPINE1 HSD17B10 3839/4885LMNA 991/4885HTT 2073/4885
US-20160045609-A1 CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE TTR, TTPA, SERPINA6 HSD17B10 2253/4885LMNA 1031/4885HTT 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback